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CORRESPONDENCE




Oculomotor schwannomas are a form of nonvestibular
schwannoma that may produce a partial or complete third
nerve palsy.1 Although often slowly progressive, oculomo-
tor schwannomas may cause recurrent or painful neurolo-
gic deficits. These tumours are distinctly uncommon, with
fewer than 107 reported cases across 70 published studies
from 1975 to 2017. Contrast-enhanced magnetic reso-
nance imaging (MRI) reveals nodular thickening and
enhancement of the oculomotor nerve.1 Surgical excision
or biopsy may cause permanent oculomotor nerve deficit;
consequently, many of these tumours are instead treated
empirically as “presumed” schwannomas.1
“Ophthalmoplegic migraine”—an entity now called
“recurrent painful ophthalmoplegic neuropathy” (RPON)
—is also considered in the differential diagnosis of painful
recurrent third nerve palsies.2,3 The International Headache
Society renamed this entity to reflect that the underlying
pathophysiology is an inflammatory cranial neuralgia and not
migraine.3,4 RPON consists of repeated attacks of ocular
motor cranial nerve palsy, often presenting in childhood,
associated with ipsilateral headache and enhancement and
thickening on MRI of the affected cranial nerve during
attacks, in the absence of any other causative lesion.3 Acute
attacks of RPON often respond to corticosteroid treatment.
Ocular motor nerve schwannomas may closely mimic
RPON, as both may produce intermittent cranial nerve
palsies and gadolinium enhancement on MRI. Schwanno-
mas, however, are generally slowly progressive and evident on
MRI even between attacks.3,4
We present a unique case of an oculomotor nerve
schwannoma masquerading as RPON. We highlight both
the potential consequences of misdiagnosis based on old
terminology and the excellent response that can be sometimes
achieved with fractionated stereotactic radiation therapy.
A 49-year-old male attended our neuro-ophthalmology
clinic for a second opinion regarding a longstanding
diagnosis of “ophthalmoplegic migraine.” He reported a
20-year history of recurrent, 3–4-day attacks of unilateral
right-sided severe head and eye pain accompanied by
pupillary mydriasis, ptosis, and inferolateral globe devia-
tion, which had become refractory to treatment with oral
prednisone, at doses escalating over 7 years to 60 mg daily
with subsequent weight gain, a cushingoid appearance,
and hypertension. Three MRI/MRA (magnetic resonance
imaging/magnetic resonance angiography) studies over the
previous 13 years had all been reported as normal.
Clinical examination, between acute attacks, revealed a best-
corrected visual acuity of 20/20 OU. Intraocular pressure was
25 mm Hg in the right eye and 24 mm Hg in the left eye.
Ocular motility was full, but he had a 10 prism diopter
exophoria. The right pupil was 0.5 mm larger than the left
pupil in bright light, and there was no relative afferent pupillary
defect. He had a 1 mm right ptosis. He had a posterior
subcapsular cataract in the right eye. Fundi were normal.
A critical re-review of his prior MRIs identified a
previously unreported nodularity along the course of the
right third nerve. A repeat contrast-enhanced MRI orbits
with dedicated fine cuts through the cavernous sinuses
indeed confirmed the presence of a focal nodular 4 mm
enhancing lesion within the right oculomotor nerve at the
level of the anterior clinoid process (Fig. 1). Its unchan-
ging and nodular appearance on MRI over many years was
consistent with schwannoma; infiltrative inflammatory or
neoplastic processes, such as sarcoidosis, tuberculosis, or
lymphoma, were thought to be exceedingly unlikely.
The patient was treated with linear accelerator–based
hypofractionated stereotactic photon radiotherapy at a
dose of 25 Gy in 5 daily fractions (5 Gy/day) using a
relocatable Aktina frame for stereotactic immobilization
(Figs. 2 and 3), with subsequent taper in steroid therapy.
Six months later, the patient reported an 80% reduction of
symptoms and a reduction of daily prednisone from 60 to
4 mg; at 18 months, he reported a 90% reduction of
symptoms and complete discontinuation of prednisone.
Follow-up clinical examinations revealed stability of the
anisocoria, reduction of the exophoria to 6 prism diopters,
and resolution of the ptosis. MRI 18 months after
radiation revealed stability of the lesion.
Treatment for cranial nerve schwannomas is aimed at
reducing or eliminating symptoms caused by the tumour
without inflicting iatrogenic damage.5 Surgical excision has
been the historical approach but is associated with morbidity.
Stereotactic radiotherapy, alternatively, distributes a targeted
dose of radiation in 3 dimensions with submillimeter preci-
sion. After radiotherapy, schwannomas may transiently enlarge,
with subsequent stabilization; delayed tumour shrinkage may
occur.6 In our patient, the excellent response of symptoms
Fig. 1—Axial T1-weighted contrast-enhanced magnetic reso-
nance imaging of the head, demonstrating nodular thickening
and enhancement of the right oculomotor nerve (arrow) at the
level of the anterior clinoid process.
without significant post-treatment radiologic change in tumour
appearance was likely due to a radiation-related reduction in
focal oculomotor nerve inflammation. This theory is sup-
ported by the fact that the patient was able to completely
discontinue prednisone therapy. Similar disconnects between
early postradiation clinical improvement and negligible radi-
ologic change have been noted with other benign tumours.7
Our case highlights 4 key points. First, oculomotor
schwannomas can closely mimic RPON in many respects.
They may both have periods of clinical quiescence punctuated
by acute exacerbations. Both conditions demonstrate cranial
nerve enhancement on MRI; however, enhancement in
RPON is diffuse rather than nodular and is only seen during
acute exacerbations of the disease. A careful radiologic search
(or critical re-review) for an oculomotor nerve schwannoma is
therefore paramount to avoid chronic, potentially indefinite,
corticosteroid therapy and its associated side effects. Second,
our case highlights the potential for improvement in symp-
toms with fractionated stereotactic radiotherapy: our patient
reported a 90% reduction of symptoms 1.5 years after
radiation with complete discontinuation of steroid therapy;
moreover, risk of iatrogenic palsy associated with surgical
excision was avoided. The outcome reflected similar favourable
rates of control (80%–90%) in vestibular schwannoma treated
with hypofractionated radiotherapy.8,9 Third, our case suggests
that control of inflammation within an oculomotor nerve
schwannoma may be more important than reduction of
tumour size. Finally, our case highlights that inaccurate
medical terminology can have adverse and long-term affects
on patient care. RPON was initially named “ophthalmoplegic
migraine,” and this misnomer encouraged physicians to think
of this entity as a primary headache syndrome and not look
more deeply for an underlying structural mimic. Although the
official terminology has been appropriately changed, the old
terminology still persists and can result in delayed diagnosis,
harm in the form of prolonged corticosteroid use, and
significant frustration for patients.
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Fig. 2—Dose distribution of stereotactic radiation delivery to
the right third nerve schwannoma. Prescribed dose was 2500
cGy in 5 daily fractions.
Fig. 3—Illustration of the radiation delivery by a single
360-degree intensity-modulated arc beam. The immobiliza-
tion frame is visible, including the stereotactic bite block.
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